720 results on '"Geisbert, Thomas W."'
Search Results
2. Monoclonal antibody therapy protects nonhuman primates against mucosal exposure to Lassa virus
3. Thermostable bivalent filovirus vaccine protects against severe and lethal Sudan ebolavirus and marburgvirus infection
4. Therapy for Argentine hemorrhagic fever in nonhuman primates with a humanized monoclonal antibody
5. Cooperativity mediated by rationally selected combinations of human monoclonal antibodies targeting the henipavirus receptor binding protein
6. Recombinant vesicular stomatitis virus-vectored vaccine induces long-lasting immunity against Nipah virus disease
7. Broadly neutralizing antibody cocktails targeting Nipah virus and Hendra virus fusion glycoproteins
8. Monoclonal antibody therapy demonstrates increased virulence of a lineage VII strain of Lassa virus in nonhuman primates.
9. Establishment of an African green monkey model for COVID-19 and protection against re-infection
10. Therapeutic administration of a cross-reactive mAb targeting the fusion glycoprotein of Nipah virus protects nonhuman primates.
11. Endotheliopathy and Platelet Dysfunction as Hallmarks of Fatal Lassa Fever
12. Marburg and Ravn Viruses Fail to Cause Disease in the Domestic Ferret ( Mustela putorius furo )
13. Efficacy of Human Monoclonal Antibody Monotherapy Against Bundibugyo Virus Infection in Nonhuman Primates
14. Comparative Transcriptomics in Ebola Makona-Infected Ferrets, Nonhuman Primates, and Humans
15. Role of Antibodies in Protection Against Ebola Virus in Nonhuman Primates Immunized With Three Vaccine Platforms
16. Postexposure Efficacy of Recombinant Vesicular Stomatitis Virus Vectors Against High and Low Doses of Marburg Virus Variant Angola in Nonhuman Primates
17. Single dose rVSVΔG-JUNVGP vaccine protects guinea pigs against lethal Junin virus challenge
18. Combination therapy protects macaques against advanced Marburg virus disease
19. A single dose investigational subunit vaccine for human use against Nipah virus and Hendra virus
20. Quadrivalent VesiculoVax vaccine protects nonhuman primates from viral-induced hemorrhagic fever and death
21. An antibody against the F glycoprotein inhibits Nipah and Hendra virus infections
22. The FDA-Approved Oral Drug Nitazoxanide Amplifies Host Antiviral Responses and Inhibits Ebola Virus
23. Antibody therapy for Lassa fever
24. Use of Single-Injection Recombinant Vesicular Stomatitis Virus Vaccine to Protect Nonhuman Primates Against Lethal Nipah Virus Disease
25. The Host Response to Smallpox: Analysis of the Gene Expression Program in Peripheral Blood Cells in a Nonhuman Primate Model
26. Reverse Genetics with a Full-Length Infectious cDNA of Severe Acute Respiratory Syndrome Coronavirus
27. An Outbreak of Ebola Virus Disease in the Lassa Fever Zone
28. Oral and Conjunctival Exposure of Nonhuman Primates to Low Doses of Ebola Makona Virus
29. Molecular Diagnostic Field Test for Point-of-Care Detection of Ebola Virus Directly From Blood
30. Passive Immunotherapy: Assessment of Convalescent Serum Against Ebola Virus Makona Infection in Nonhuman Primates
31. Field Validation of the ReEBOV Antigen Rapid Test for Point-of-Care Diagnosis of Ebola Virus Infection
32. Analytical Validation of the ReEBOV Antigen Rapid Test for Point-of-Care Diagnosis of Ebola Virus Infection
33. Neutralizing the Threat: Pan-Ebolavirus Antibodies Close the Loop
34. Antibodies from Sierra Leonean and Nigerian Lassa fever survivors cross-react with recombinant proteins representing Lassa viruses of divergent lineages
35. Intranasal exposure of African green monkeys to SARS-CoV-2 results in acute phase pneumonia with shedding and lung injury still present in the early convalescence phase
36. Prior vaccination with rVSV-ZEBOV does not interfere with but improves efficacy of postexposure antibody treatment
37. Immune correlates of postexposure vaccine protection against Marburg virus
38. Rational design of universal immunotherapy for TfR1-tropic arenaviruses
39. Antagonism of STAT1 by Nipah virus P gene products modulates disease course but not lethal outcome in the ferret model
40. Antibodies periodically wax and wane in survivors of Ebola
41. Single-dose VSV-based vaccine protects cynomolgus macaques from disease after Taï Forest virus infection.
42. High-Avidity Anti-Filovirus IgG Elicited Using Protein Subunit Vaccines Does Not Correlate with Protection.
43. Modelling Marburg Virus Disease in Syrian Golden Hamsters: Contrasted Virulence Between Angola and Ci67 Strains.
44. Perspectives on Advancing Countermeasures for Filovirus Disease: Report From a Multisector Meeting.
45. Limited Benefit of Postexposure Prophylaxis With VSV-EBOV in Ebola Virus–Infected Rhesus Macaques.
46. The Mucin-Like Domain of the Ebola Glycoprotein Does Not Impact Virulence or Pathogenicity in Ferrets.
47. Long-term Prophylaxis Against Aerosolized Marburg Virus in Nonhuman Primates With an Afucosylated Monoclonal Antibody.
48. Natural History of Nonhuman Primates After Oral Exposure to Ebola Virus Variant Makona.
49. A Highly Attenuated Panfilovirus VesiculoVax Vaccine Rapidly Protects Nonhuman Primates Against Marburg Virus and 3 Species of Ebola Virus.
50. Pathogenesis of Aerosolized Ebola Virus Variant Makona in Nonhuman Primates.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.